The efficacy of intravenous immunoglobulin(IVIG) for the maintenance phase of treatment for children with acute lymphoblastic leukemia(ALL)

The efficacy of intravenous immunoglobulin(IVIG) for the maintenance phase of treatment for children with acute lymphoblastic leukemia(ALL) - The efficacy of intravenous immunoglobulin(IVIG) for the maintenance phase of treatment for children with acute lymphoblastic leukemia(ALL)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015179

Enrollment

Registered

2014-09-16

Start date

2014-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Interventions

administration of immunoglobulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute lymphoblastic leukemia

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The rate of infection.	—

Countries

Japan

Contacts

Public ContactAtsushi Narita

Nagoya University Graduate School of Medicine Department of pediatrics,

stanza-la-speranza@nifty.com052-744-2294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026